Vanguard Global Advisers’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
Other funds holding ABEO
ACM
AIC
Vanguard Global Advisers's ABEO Position: Q3 2026 in Review
Vanguard Global Advisers increased its Abeona Therapeutics (ABEO) stake by 1.1% in Q3 2026, buying an estimated $1.25K and bringing the position to 18,810 shares worth $98.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2779.
Vanguard Global Advisers first reported a position in ABEO in Q1 2026 and has held it in 3 quarters since. The position peaked at $115K in Q2 2026. 116 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.
- Vanguard Global Advisers held 18,810 shares of Abeona Therapeutics worth $98.8K as of Q3 2026.
- Vanguard Global Advisers bought 202 Abeona Therapeutics shares in Q3 2026, an estimated $1.25K.
- Abeona Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2779 holding.
- Vanguard Global Advisers first reported a position in Abeona Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Abeona Therapeutics position peaked at $115K in Q2 2026.
- 116 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.